Sangamo Therapeutics (SGMOQ) Current Assets (2010 - 2025)

Sangamo Therapeutics has reported Current Assets for 16 years, with the latest figure at $35.8 million in Q4 2025.

• On a quarterly basis, Current Assets fell 30.68% year-over-year to $35.8 million in Q4 2025; TTM through Dec 2025 was $35.8 million, a 30.68% decrease from a year earlier, with the FY2025 full-year figure at $35.8 million, down 30.68% from the prior year.
• Current Assets was $35.8 million for Q4 2025 at Sangamo Therapeutics, down from $44.1 million in the prior quarter.
• The five-year high for Current Assets was $606.9 million in Q1 2021, with the low at $35.8 million in Q4 2025.
• Average Current Assets over 5 years is $217.1 million, with a median of $153.6 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Current Assets soared 63.62% in 2021, then slumped 74.89% in 2024.
• Over 5 years, Current Assets stood at $398.8 million in 2021, then fell by 24.69% to $300.3 million in 2022, then plunged by 68.59% to $94.3 million in 2023, then slumped by 45.2% to $51.7 million in 2024, then sank by 30.68% to $35.8 million in 2025.
• The last three Current Assets figures came in at $35.8 million (Q4 2025), $44.1 million (Q3 2025), and $49.9 million (Q2 2025), per Business Quant data.